ClinicalTrials.gg

Program

capivasertib

Also written as “Capivasertib”, “AZD5363” and “Intermittent dosing of AZD5363”.

Its studies are mostly in Breast Neoplasms · Prostatic Neoplasms · Triple Negative Breast Neoplasms · Hematologic Neoplasms, led by AstraZeneca.

Furthest: phase 3, since May 20, 201923 company-led studies, 9 open or runningNext primary completion: Nov 1, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca239 open or runningphase 3since May 20, 2019Oct 21, 2010Nov 1, 2027phase 3 · NCT04862663

Also a collaborator on its studies: apices-soluciones-s-l, parexel and quotient-sciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Oct 21, 2010.

  1. Jul 9, 2020Phase 3 study in Prostatic NeoplasmsNCT04493853 · 1,012 enrolled · United States, Argentina, Australia and more
  2. Dec 15, 2020Phase 1 study in Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)NCT04712396 · 11 enrolled · Germany
  3. Jan 15, 2021Phase 1 study in Advanced Solid TumoursNCT04742036 · 16 enrolled · China
  4. Mar 17, 2021Phase 3 study in Locally Advanced (Inoperable) or Metastatic Breast CancerNCT04862663 · 893 enrolled · United States, Argentina, Australia and more
  5. Jun 28, 2021Phase 1 study in Hematologic NeoplasmsNCT04944771 · 48 enrolled · Germany
  6. Jul 1, 2021Phase 1 study in Solid TumourNCT04958226 · 21 enrolled · United States
  7. Jul 19, 2021Phase 2 study in RecurrenceNCT05008055 · 30 enrolled · United States, Canada, Denmark and more
  8. Mar 18, 2022Phase 3 study in Prostatic NeoplasmsNCT05348577 · 1,035 enrolled · United States, Australia, Belgium and more
  9. Apr 11, 2022Phase 1 study in Healthy VolunteerNCT05419401 · 7 enrolled · United Kingdom
  10. Sep 9, 2024Phase 3 study in Breast NeoplasmsNCT06635447 · 293 enrolled · China
  11. Nov 28, 2024Phase 3 study in Breast NeoplasmsNCT06764186 · 101 enrolled · Spain
  12. Jul 17, 2025Phase 1 study in Healthy ParticipantsNCT07088913 · 20 enrolled · United States
  13. Nov 17, 2025Phase 1 study in Healthy ParticipantsNCT07241065 · 42 enrolled · Germany
  14. Jan 7, 2026Phase 1 study in Moderate Hepatic ImpairmentNCT07343960 · 20 planned · United States

Ahead

  1. Nov 11, 2026Primary completion: phase 1 study in Moderate Hepatic ImpairmentNCT07343960
  2. Nov 1, 2027Primary completion: phase 3 study in Locally Advanced (Inoperable) or Metastatic Breast CancerNCT04862663
  3. Nov 30, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT06764186

TargetBeta

“Serine/threonine-protein kinase AKT inhibitor”ChEMBL 37, by rule

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07343960Moderate Hepatic Impairment · United States1RecruitingNov 11, 202620
NCT07241065Healthy Participants · Germany1CompletedJul 20, 202642
NCT07088913Healthy Participants · United States1CompletedFeb 20, 202620
NCT06764186Breast Neoplasms · Spain3Active, not recruitingNov 30, 2027101
NCT06635447Breast Neoplasms · China3Active, not recruitingOct 31, 2026293
NCT05419401Healthy Volunteer · United Kingdom1CompletedJul 12, 20227
NCT05348577Prostatic Neoplasms · United States, Australia, Belgium and more3Active, not recruitingMar 4, 20261,035
NCT05008055Recurrence · United States, Canada, Denmark and more2CompletedAug 22, 202330
NCT04958226Solid Tumour · United States1CompletedFeb 6, 202321
NCT04944771Hematologic Neoplasms · Germany1CompletedMay 4, 202248
NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer · United States, Argentina, Australia and more3Active, not recruitingNov 1, 2027893
NCT04742036Advanced Solid Tumours · China1CompletedJul 29, 202216
NCT04712396Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) · Germany1CompletedMar 25, 202111
NCT04493853Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingOct 7, 20241,012
NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer · United States, Argentina, Australia and more3Active, not recruitingMay 9, 2023818
NCT04087174Prostatic Neoplasms · United States, Spain1CompletedJun 22, 202127
NCT03997123Triple Negative Breast Neoplasms · United States, Argentina, Brazil and more3Active, not recruitingMar 16, 2026923
NCT03742102Triple Negative Breast Neoplasms · United States, Canada, Poland and more2Active, not recruitingNov 29, 2024243
NCT01895946Advanced Solid Malignancy, · Netherlands, United Kingdom1CompletedFeb 201533
NCT01692262Prostatic Neoplasms · United States, United Kingdom1CompletedJun 201459
NCT01625286Breast Neoplasms · Bulgaria, Canada, Czechia and more2CompletedJan 28, 2017148
NCT01353781Advanced Solid Malignancy · Japan1CompletedJul 201439
NCT01226316Breast Neoplasms · United States, Canada, Denmark and more1CompletedApr 26, 2019285

How it is read

Names in the registry

  • “Capivasertib”, 16 entries
  • “AZD5363”, 7 entries
  • “Intermittent dosing of AZD5363”, 3 entries
  • “AZD5363 when combined with weekly paclitaxel.”, 2 entries
  • “capivasertib”, 1 entry

Codes read as this program: AZD5363.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.